CA2585279A1 - 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease - Google Patents

2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Download PDF

Info

Publication number
CA2585279A1
CA2585279A1 CA002585279A CA2585279A CA2585279A1 CA 2585279 A1 CA2585279 A1 CA 2585279A1 CA 002585279 A CA002585279 A CA 002585279A CA 2585279 A CA2585279 A CA 2585279A CA 2585279 A1 CA2585279 A1 CA 2585279A1
Authority
CA
Canada
Prior art keywords
group
alkyl
compound
halogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002585279A
Other languages
English (en)
French (fr)
Inventor
Craig A. Coburn
M. Katharine Holloway
Shawn J. Stachel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2585279A1 publication Critical patent/CA2585279A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA002585279A 2004-10-29 2005-10-25 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Abandoned CA2585279A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62344104P 2004-10-29 2004-10-29
US60/623,441 2004-10-29
PCT/US2005/039932 WO2006060109A1 (en) 2004-10-29 2005-10-25 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CA2585279A1 true CA2585279A1 (en) 2006-06-08

Family

ID=36565355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002585279A Abandoned CA2585279A1 (en) 2004-10-29 2005-10-25 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Country Status (7)

Country Link
US (1) US7932275B2 (enExample)
EP (1) EP1807396B1 (enExample)
JP (1) JP2008518969A (enExample)
CN (1) CN101052618A (enExample)
AU (1) AU2005310239A1 (enExample)
CA (1) CA2585279A1 (enExample)
WO (1) WO2006060109A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111465603A (zh) * 2017-12-19 2020-07-28 勃林格殷格翰国际有限公司 作为γ-分泌酶调节剂的三唑并吡啶

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1940406A4 (en) * 2005-10-21 2009-11-18 Merck & Co Inc POTASSIUM CHANNEL INHIBITORS
EP2402317B1 (en) 2006-03-31 2013-07-03 Novartis AG DGAT inhibitor
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
CA2714058A1 (en) 2008-02-28 2009-09-03 Ivory D. Hills 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JP2014524472A (ja) 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN111533684B (zh) * 2020-05-29 2021-10-29 四川大学 一种吡啶化合物烯基化的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
MXPA03001136A (es) * 2000-08-11 2003-06-24 Eisai Co Ltd Compuesto de 2-aminopiridina y uso medico del mismo.
US6951946B2 (en) * 2002-03-19 2005-10-04 Lexicon Pharmaceuticals, Inc. Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates
WO2003106405A1 (en) 2002-06-01 2003-12-24 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
CA2529739A1 (en) 2003-06-16 2005-01-20 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US20080287399A1 (en) 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111465603A (zh) * 2017-12-19 2020-07-28 勃林格殷格翰国际有限公司 作为γ-分泌酶调节剂的三唑并吡啶
CN111465603B (zh) * 2017-12-19 2024-01-09 勃林格殷格翰国际有限公司 作为γ-分泌酶调节剂的三唑并吡啶

Also Published As

Publication number Publication date
US7932275B2 (en) 2011-04-26
WO2006060109A1 (en) 2006-06-08
EP1807396A1 (en) 2007-07-18
JP2008518969A (ja) 2008-06-05
CN101052618A (zh) 2007-10-10
AU2005310239A1 (en) 2006-06-08
EP1807396A4 (en) 2009-09-09
US20080161363A1 (en) 2008-07-03
EP1807396B1 (en) 2013-06-26
WO2006060109B1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
EP1807396B1 (en) 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
KR101152690B1 (ko) 염증성 질환과 당뇨병을 치료하기 위한 글루코코르티코이드 리간드로서의 1,1,1-트리플루오로-4-페닐-4-메틸-2-(1Ｈ-피롤로〔2,3-ｃ 〕피리딘-2-일메틸)펜탄-2-올 유도체 및 관련된 화합물
EP1841426B1 (en) Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
EP2262766A2 (en) Amide compounds, compositions and uses thereof
EP1732906A1 (en) 2-aminothiazole compounds useful as aspartyl protease inhibitors
JP2010518026A (ja) ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物
JP6908623B2 (ja) テトラヒドロイソキノリン誘導体
TWI458720B (zh) 苯基或吡啶基－乙炔基衍生物
CA2570995A1 (en) Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2019063748A1 (en) INHIBITORS OF ROR-GAMMA
CN101605795A (zh) 三环化合物及其药物用途
CN110049985B (zh) 作为RORγ调节剂的杂环砜类
EP1951709B1 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2019144765A1 (zh) 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
WO2023122093A1 (en) Rev-erb agonists for th17-mediated inflammatory disorders
US20090170830A1 (en) Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
EP1912963B1 (en) Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007019080A2 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
CN1976705B (zh) 作为用于治疗炎性疾病和糖尿病的糖皮质激素配体的1,1,1-三氟-4-苯基-4-甲基-2-(1h-吡咯并[2,3-c]吡啶-2-基甲基)戊-2-醇衍生物和相关化合物
WO2021020363A1 (ja) 複素環化合物
JPWO2013100018A1 (ja) 複素環化合物
HK40006155B (zh) 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
HK1198030B (en) Amide compounds, compositions and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued